Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
These are pathway-level variants: they do not predict response to any specific compound, but they describe the biology a clinician is prescribing into
Research focus Summary of contexts in which this compound appears in the preclinical literature
Obesity and Cardiovascular Disease
The GHR antagonist pegvisomant is an analog of GH that competes with GH for receptor binding and consequently blocks GHR signal transduction
US$ 23.73
US$ 27.36
US$ 25.47
US$ 23.32
US$ 26.83
US$ 29.08
US$ 20.08
